You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models

Article metrics

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Original research
Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models

 

Online download statistics by month:

Online download statistics by month: February 2020 to February 2023

AbstractFullPdf
Feb 2020473473149
Mar 202032132187
Apr 202019019027
May 202011111116
Jun 2020757522
Jul 2020787818
Aug 2020666630
Sep 202011511525
Oct 2020828224
Nov 202010510431
Dec 202010710738
Jan 202115715734
Feb 202114414442
Mar 202127227263
Apr 202116316347
May 202110610632
Jun 202112512547
Jul 202114214242
Aug 202113913947
Sep 202113613656
Oct 202117617667
Nov 202114314174
Dec 202111411432
Jan 2022748535
Feb 2022849938
Mar 202212512866
Apr 202212112937
May 202211413450
Jun 202210611134
Jul 202210210834
Aug 202210410931
Sep 20229710297
Oct 202212613346
Nov 202210210554
Dec 202210811230
Jan 2023949840
Feb 202312812848
Total502551181690